| 货号 | 10010334-10mg |
| 描述 | Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the “statin” class of cholesterol-lowering drugs.1 Fluvastatin acts as a competitive inhibitor of HMG-CoA reductase with respect to binding of the substrate HMG-CoA (Ki = 0.3 nM) but not with respect to binding of NADPH.2,3 It is marketed under the trade name Lescol® for the treatment of hypercholesterolemia in the prevention of cardiovascular disease. When fluvastatin was administered in a clinical trial to patients undergoing percutaneous coronary intervention, LDL cholesterol levels were reduced by 27% after six weeks of treatment with a dose of 40 mg/kg twice a day compared to placebo.4 |
| 别名 | Leschol®; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nature Reviews.Drug Discovery 2(7), 517-526 (2003). 2.Istvan, E.S., and Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164 (2001). 3.Corsini, A.,Maggi, F.M., and Catapano, A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacological Research 31(1), 9-27 (1995). 4.Serruys, P.W.J.C.,de Feyter, P.,Macaya, C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. Journal of the American Medical Association 287(24), 3215-3222 (2002). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 411.5 |
| 分子式 | C24H26FNO4 |
| CAS号 | 93957-54-1 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |